Variations in the management of acute exacerbations of chronic obstructive pulmonary disease

Canadian Respiratory Journal

Volumn 20, Issue 3, 2013, Pages 175-179

  Sandhu, Supna K ^a   Chu, Jackson ^a   Yurkovich, Marko ^a   Harriman, David ^a   Taraboanta, Catalin ^a   FitzGerald, J Mark ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chronic obstructive lung disease; Health outcomes; Variations in practice

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PLUS SALMETEROL; IPRATROPIUM BROMIDE; LONG ACTING BETA AGONIST; PREDNISONE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE; AGED; ARTICLE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 84882426646     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/501038     Document Type: Article

References (14)

1. Benady S. The Human and Economic Burden of COPD: A Leading Cause of Hospital Admission in Canada. Report by the Canadian Thoracic Society, 2010. (Accessed November 2011).
2. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008:15(Suppl A).
3. Mittmann N, Kuramoto L, Seung SJ, et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med 2008;102:413-21.
4. GOLD Executive Committee. Global initiative for chronic Obstructive Pulmonary Disease: Pocket guide to COPD diagnosis, management, and prevention. Updated 2008. . (Accessed June 2011).
5. FitzGerald JM. Targeting lung attacks. Thorax 2011;66:365-6.
6. Aaron SD, Vandemheen KL, Fergusson D, et al; for the Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone/salmeterol for chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2007;146:545-55.
7. Rowe BH, Cydulka RK, Tsai CL, Clark S, Sinclair D, Camargo CA Jr. Comparison of Canadian versus United States emergency department visits for chronic obstructive pulmonary disease exacerbation. Can Respir J 2008;15:295-301.
8. Lodewijckx C, Sermeus W, Vanhaecht K, et al. Inhospital management of COPD exacerbations: A systematic review of the literature with regard to adherence to international guidelines. J Eval Clin Pract 2009;15:1101-10.
9. Lindenauer PK, Pekow P, Gao S, Crawford AS, Gutierrez B, Benjamin E. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006;144:894-903.
10. Bratzler DW, Oehlert WH, McAdams LM, Leon J, Jiang H, Piatt D. Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly: Physician practices in the community hospital setting. J Okla State Med Assoc 2004;97:227-32.
11. Gibson PG, Wlodarczyk JH, Wilson AJ, Sprogis A. Severe exacerbation of chronic obstructive airways disease: Health resource use in general practice and hospital. J Qual Clin Pract 1998;18:125-33.
12. Phanareth K, Hansen LS, Christensen LK, Laursen LC, Hansen EF. Treatment of acute severe asthma and chronic obstructive pulmonary disease in Danish hospitals. Do national recommendations improve on the quality of the treatment? Respir Med 2002;96:653-58.
13. Hurst JR, Donaldson GC, Quint JK, Goldring JJP, Baghai-Ravary F, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:369-74.
14. Gunen G, Gulbas G, In E, Yetkin O, Hacievliyagil SS. Venous thromboemboli and exacerbations of COPD. Eur Respir J 2010;35:1243-8.